Phase 3 N=3,556 Preventing Sexual Transmission of HIV With Anti-HIV Drugs
HIV Infections
Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=106 Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
Risk Behavior · Medication Adherence · HIV
Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants
N/A N=37 Cardiovascular Prevention for Persons With HIV
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
Phase 4 N=4,447 PrEP Implementation for Mothers in Antenatal Care
HIV Infections · Pregnancy Related
Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years
Phase 2 N=267 Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
HIV Prevention · HIV Infections
Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05
N/A N=128 Podcasting HIV Prevention Within African American Communities
HIV Prevention
Primary: Change in Condom Use Self-Efficacy (From Baseline to 1 Month Follow-up) — 4.4 score on a scale — p=<.001
N/A N=46 A Key Link for Transmission Prevention
HIV
Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened
N/A N=322 HIV Oral Testing Infographic Experiment
HIV/AIDS
Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale
N/A N=1,967 Implementing a Comprehensive Prevention of Mother-to-Child Transmission of HIV Program for South African Couples
HIV · Pregnancy
Primary: Dried Blood Spot Analysis of Medication Adherence- Mother and Infant — 56; 157; 35; 183 Participants
Phase 2 N=149 Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Anal Cancer · Nonneoplastic Condition · Penile Cancer
Primary: Incidence of AIN or Anal/Perianal Condyloma Associated With HPV 6 DNA — 0.0; 11.1 Events per 100 person years — p=0.112
Phase 3 N=2,499 Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
HIV Infections
Primary: HIV Seroconversion — 48; 83 Participants — p=0.002
N/A N=20 Innovations in HIV Testing (TI)
Human Immunodeficiency Virus
Primary: Qualitative Summaries of Participant Experience in Focus Group Discussions — 100; 7; 26; 10 number of times reported in FGD
Phase 3 N=4,758 Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
HIV-1 Infections · HIV Infections
Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001
Phase 2 N=746 A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs
HIV Infections · Sexually Transmitted Diseases
Primary: Sex Risk Behaviors: Number of Sex Partners (>=2 Sex Partners) — 17; 29; 50; 53 participants — p=<0.01
Phase 2 N=92 Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers
HIV Infection
Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants
N/A N=26 Pre-Exposure Prophylaxis in the Emergency Department
HIV/AIDS · PrEP
Primary: Engagement in Care (Implementation Component) — 1; 1 Participants
N/A N=212 A Risky Sex Prevention Intervention for Middle School Age Minority Girls
HIV · Risky Sex Prevention
Primary: Adolescent Sexual Activity Index — 1.39; 1.45; 2.12; 1.90 score on a scale — p=0.62
Phase 1 N=150 Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
Cervical Cancer · Nonneoplastic Condition · Precancerous Condition
Primary: Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0 — 6.0 Grade 3/4 adverse events per 100 patient
Phase 1 N=23 HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Phase 4 N=136 Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
HIV Prevention
Primary: Adherence to PrEP — 22; 11; 30; 54 Participants
N/A N=1,578 Online Social Networking for HIV Prevention
HIV
Primary: Proportion of Condom Usage — .68; .56 proportion of condom use
N/A N=117 A Digital Intervention for HIV Prevention in Black Adolescent Girls
HIV · Risk Reduction Behavior
Primary: Feasibility Assessed Using Change in Retention Rates — 97.5; 97.4; 97.5; 100 percentage of questionnaires returned
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
N/A N=59 A Comprehensive HIV Prevention Package for South African Adolescent Girls and Young Women: IMARA SA
Sexually Transmitted Infection · Hiv
Primary: Number of AGYW Who Tested Positive for a Sexually Transmitted Infection (STI) — 4; 6 Participants — p=0.15
N/A N=297 A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
HIV/AIDS · Hypertension · Hyperlipidemias
Primary: Systolic Blood Pressure — 134.9; 134.9; 129.9; 136.3 model estimated mmhg
Phase 4 N=212 Alignment of PrEP Use With HIV Risk in Young Women and Men
Pre-Exposure Prophylaxis · Sexually Transmitted Diseases, Bacterial · HIV Infections
Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits
Phase 3 N=1,456 Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
Human Immunodeficiency Virus
Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants
N/A N=196 Prevention and Risk: Treatment With a New Emphasis on Relationships
Adherence, Medication · Risk Reduction · Drug Use
Primary: Illicit Drug Use Days — 1.49; .80; 1.16; 0.83 days — p=.433
N/A N=28 Youth Ending the HIV Epidemic
HIV/AIDS · Mobile Health · Young Adults
Primary: Feasibility: Rate of Participant Retention — 22 Participants
Phase 2 N=58 ARVs to Prevent Breastmilk HIV:Viral and Immune Responses
HIV Infections
Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml